EMA approves Votrient (Glaxo Smith Kline) for patients with Soft Tissue Sarcoma

The European Commission has granted marketing authorisation for the use of Votrient (pazopanib), from Glaxo Smith Kline, for treatment of patients with advanced Soft Tissue Sarcoma (aSTS) who have received prior chemotherapy or have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only been established in certain STS histological tumour subtypes. According to results of the Phase III PALETTE trial published in May 2012, the drug nearly tripled progression-free survival compared with placebo. The FDA also approved Votrient in April 2012 for use with aSTS following Phase III trials which included patients with more than 20 subtypes of sarcoma.